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Abstract: The use of a focused laser beam to create a sub-micron hole in 
the  plasma  membrane  of  a  cell  (photoporation),  for  the  selective 
introduction  of  membrane  impermeable  substances  (optical  injection) 
including nucleic acids (optical transfection), is a powerful technique most 
commonly  applied  to  treat  single  cells.  However,  particularly  for 
femtosecond  photoporation,  these  studies  have  been  limited  to  low 
throughput, small-scale studies, because they require sequential dosing of 
individual cells. Herein, we describe a microfluidic photoporation system 
for  increased  throughput  and  automated  optical  injection  of  cells. 
Hydrodynamic  focusing  is  employed  to  direct  a  flow  of  single-file  cells 
through  a  focused  femtosecond  laser  beam  for  photoporation.  Upon 
traversing the beam, a number of transient pores potentially open across the 
extracellular membrane, which allows the uptake of the surrounding fluid 
media into the cytoplasm, also containing the chosen injection agent. The 
process  is  entirely  automated  and  a  rate  of  1  cell/sec  could  readily  be 
obtained, enabling several thousand cells to be injected per hour using this 
system. The efficiency of optically injecting propidium iodide into HEK293 
mammalian cells was found to be 42 ± 8%, or 28 ± 4% taking into account 
the requirement of post-injection viability, as tested using Calcein AM. This 
work now opens the  way for combining photoporation with microfluidic 
analyses, sorting, purification or on-chip cell culture studies. 
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1. Introduction 
Optical injection is a promising technique for transiently perforating the membrane of living 
biological cells, using a tightly focused laser beam to allow impermeable molecules, such as 
drugs,  dyes  or  nucleic  acids  (including  plasmid  DNA),  to  pass  into  the  cytoplasm.  First 
demonstrated by Tsukakoshi et al. in 1984 [1], a wide spectrum of laser sources have since 
been successfully implemented, including continuous wave (CW) at 405 nm [2,3] and 488 nm 
[4–6] as well as pulsed laser sources of nano-, pico- [1,7–9] and most notably of femtosecond 
(fs)  pulse  durations  in  the  near  infrared  [10–23],  and  at  2080  nm  (Ho:YAG)  [8,24]. 
Femtosecond optical injection is a non-invasive and sterile technique, with recent studies in 
delivering plasmid DNA for subsequent transfection of the cells with efficiencies of up to 
80%  [13]  and  demonstrating  excellent  cell  viability.  Optical  transfection  has  been 
demonstrated on a wide range of biological cells, both plant [9] and animal cells, including 
mammalian neurons [11] and stem cells [13,18]. Indeed, it has recently been reported that 
optical injection can be utilized to differentiate mouse embryonic stem cell colonies into the 
extraembryonic endoderm [13]. 
Nano-  and  picosecond  optical  injection  can  be  used  to  treat  many  dozens  of  cells 
simultaneously [1,7–9], but is associated with a large “zone of destruction,” with viable cell 
permeation  only  occurring  on  the  periphery  of  a  laser-induced  acoustic  shockwave  [25]. 
Femtosecond and CW sources facilitate the treatment of single cells, resulting in improved 
efficiency and viability. The most widely used laser source is the Kerr lens mode-locked fs 
Titanium:Sapphire laser, which when focused through a high numerical aperture lens will 
produce a sub-micron diffraction-limited laser spot, with peak powers of the order of KW’s at 
the focus. When delivered to the cell membrane, this will generate multi-photon absorption 
and ionization that forms a low-density free-electron plasma within the lipid bilayer [26]. The 
transient interaction invokes the cell to uptake femtoliter volumes of the extra-cellular fluid, 
containing the nanoparticles [21], charged molecules (such as DNA) or other reagents for 
insertion into the cell. Importantly, the power levels used are below the threshold for optical 
breakdown [26]; thus minimizing collateral damage and maintaining the viability of the cell. 
Cells are targeted one at a time and as such femtosecond optical injection is an excellent tool 
for single cell analysis, or for porating small populations of a few tens of cells. 
However, the ability to localize the photoporation effect to a precise region on a single cell 
has been both advantageous and limiting. Whilst this methodology is suitable for single cell 
analysis, dosing more than ~100 cells is time consuming. This limitation has prohibited larger 
studies on cell populations. One method for improving the throughput of fs optical injection is 
#129403 - $15.00 USD Received 1 Jun 2010; revised 19 Jul 2010; accepted 2 Aug 2010; published 9 Aug 2010
(C) 2010 OSA 1 September 2010 / Vol. 1,  No. 2 / BIOMEDICAL OPTICS EXPRESS  529to  remove  the  necessity  for  manually  locating  the  beam  focus  on  each  cell.  This  has 
previously been achieved using a spatial light modulator (SLM) to produce a “diffraction-
free” Bessel beam, controlled by a “point and click” interface, allowing a user to select cells at 
will on the screen for injection, without the need for careful positioning of the beam focus 
[27]. The method addressed in this work is to introduce a cell delivery method that streams 
continually cells through the beam for automated injection. Indeed, this has previously been 
demonstrated by making use of microfluidic systems combined with microinjection [28,29] 
and electroporation [30–34]. 
In this study, we report a significant step towards high cell throughputs and automated 
optical  injection  by  making  use  of  microfluidic  cell  delivery  which  we  demonstrate  on  a 
mammalian  cell  line.  The  precision  of  focused  femtosecond  pulses  was  combined  with 
hydrodynamic  focusing,  to  produce  a  single-file  flow  of  cells  through  the  laser  beam  for 
optical injection. The injection efficiency and viability of this new system was determined 
using propidium iodide (PI) dye and calcein AM (CAM) respectively, and was found to be on 
par with ‘static’ fs photoporation studies of adherent cells. Flow rates of one cell per second 
could readily be obtained, enabling several thousand viable injected cells to be produced in an 
hour. This work indicates optical injection as a favorable alternative to other techniques such 
as electroporation [35], microinjection [36], ballistic methods [37], lipofection [38] or viral 
[39]  mediated  transfection.  The  combination  of  microfluidic  photoporation  with  on-chip 
sample mixing, cell culture or analysis or alternatively microfluidic sorting schemes, such as 
fluorescence/Raman activated cell sorting (FACS/RACS [40,41]) or passive optical sorting 
[42,43] can now all be envisaged. 
2. Microfluidic chip and setup 
The microfluidic chips for this study were fabricated in poly-dimethylsiloxane (PDMS) using 
standard soft lithography procedures [44]. The PDMS chip was designed to have an inlet and 
outlet port for the insertion and collection of cells, and a hydrodynamic focusing region to 
force the cell sample into a thin (sub-cell sized) stream down the center of the fluidic channel 
thereby directing all cells through the photoporation beam. Briefly the  fluidic design  was 
composed in a CAD software package and printed to high resolution transparency (Circuit 
Graphics Ltd). Photolithography was used to form a mold in 70 µm thick SU-8 (Microchem) 
resist on a silicon wafer and silanized with perfluorooctyltrichlorosilane (S13125, Flurochem). 
Two-part PDMS (Sylgard 184, Dow Corning) was mixed in a 1:10 weight ratio, degassed, 
poured on to the mold and baked at 65°C for two hours. The channel dimensions were 150 µm 
wide by 70 µm high throughout except at the reservoirs that were 3 mm in diameter. 
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Fig. 1. (a) Image of the PDMS chip showing micro-centrifuge tubes for cell insertion and 
collection, and the two inlet pipes on the left for buffer and sample flow and a single outlet pipe 
on the right. (b) Microfluidic channel layout on the PDMS chip (not to scale). The cells are first 
inserted directly into chip via an adapted micro-centrifuge tube (left-most). The three syringe 
pumps  then  drive  the  fluid  as  indicated  by  the  arrows.  Cells  pass  into  the  hydrodynamic 
focusing junction, forcing them to flow one at a time through the femtosecond laser beam (as 
focused  into  the  chip  via the  objective  lens),  where  optical  injection  occurs.  The  beam is 
positioned approximately 300 µm downstream of the hydrodynamic focusing junction. Cells 
come to rest under the second micro-centrifuge tube, ready for collection with a pipette for 
culture and/or analysis. 
To incorporate cell injection and collection ports, it was necessary to define a second 
section of PDMS on top of the first to provide sufficient support for the cell ports, as can be 
observed in Fig. 1. Once cured the PDMS was peeled from the mold, inlets punched (Harris 
Micropunch) and irreversibly sealed to a type-1 coverslip (VWR International) using a hand-
held plasma treater [45]. The inlet sizes were 1.2 mm and 3 mm for the pipes and 0.5 ml 
micro-centrifugation tubes respectively. Adapted 0.5 ml micro-centrifugation tubes (cap and 
base removed) were later inserted into the punched holes to act as cell injection and collection 
reservoirs. 
Several features were incorporated into the fluidic setup to minimize fluctuations in the 
fluid flow in order to obtain a steady and reproducible flow of cells over the course of the 
experiment. Three syringe pumps (Harvard Apparatus, Pico Plus) were used in a “push-pull” 
configuration to generate stable hydrodynamic focusing: one to drive the sample stream, one 
for the buffer streams and a third as a suction pump on the outlet. Rigid Radel R (Upchurch) 
tubing was used to interface the chip to the syringe pumps (see Fig. 2), providing significantly 
more stable flow than the Tygon R3603 flexible tubing, that was used purely for interfacing 
the peristaltic pump. Four-way L-junction switching valves (Upchurch) were used to connect 
the peristaltic and syringe pump fluid lines, allowing the chip and pipes to be flushed and 
filled as desired using the peristaltic pump, but also isolated to just the syringe pump lines 
when running the experiment. Gastight (Hamilton) 100 µl syringes were used with the syringe 
pumps. 
 
Fig. 2. Fluidic setup required for cleaning, sterilizing and flowing cells. Cleaning, sterilizing 
and filling of the fluidics with cell medium is conducted using the peristaltic pump. Syringe 
pumps are used for flowing of the cells for optical injection, and operate in a “push-pull” 
configuration to obtain stable fluid flow. Layout of the PDMS microfluidic chip is also shown, 
which matches with Fig. 1. The injection agent is added the Opti-MEM
® before filling the chip 
and piping at the start of the experiment. 
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a channel width of 150 µm, a 1:5 ratio gives 13%, or 20 µm which is approximately one cell 
width [46]. Flow rates were controlled via a Labview interface and set to 7 µlhr
−1 and 70 
µlhr
−1 for sample and buffer pumps respectively. Depending on the confluency of the cell 
sample, this gave a rate of 1 cell per second, and a cell velocity of 1100 ± 100 µms
−1. It should 
be noted that the velocity of the cells is lower than the peak fluid velocity in the channel, 
because the cells were situated in the lower half of the channel due to gravity. As the cells are 
denser than the fluid medium, this allows them to rest on the bottom of the injection reservoir 
at the start of the experiment. At the start of an experiment, there will be some lift of the cells 
due to Bernoulli lift in a parabolic flow profile, but at these flow rates it was not expected to 
contribute to an elevation of even 10 µm from the channel base. The clearest brightfield image 
of cells, as they traversed the laser spot, was at a position of 6 µm above the coverslip. The 
cells were observed to flow at similar velocities, indicating similar positions in a parabolic 
shaped  flow  profile.  The  flow  rates  used  throughout  were  first  determined  empirically  to 
provide single file flow of cells at the required velocity of 1100 µms
−1. 
3. Cell culture, preparation and collection 
Propidium iodide (PI, Sigma-Aldrich) is a membrane impermeable stain commonly used in 
proof of principle cell injection studies. PI is only taken up by cells whose membranes have 
been compromised and will be excluded by living viable cells. It interacts with the DNA of 
the host cell by binding to specific nucleotides within the DNA strand. Once the binding 
occurs,  and  under  the  right  excitation  illumination,  the  PI  molecules  will  exhibit  intense 
fluorescence  at  617  nm.  In  order  to  verify  PI  uptake  and  confirm  cell  viability,  upon 
treatment, the cells were stained with the membrane permeable neutral vital dye Calcein-AM 
(CAM, Invitrogen), which is rapidly converted by cell esterases into calcein that fluorescences 
at  530  nm  within  a  viable  cell  [47].  These  two  fluorescent  dyes  therefore  work  well  in 
conjunction to identify viable and successfully optically injected cells. 
Human embryonic kidney (HEK293) cells were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM, Sigma-Aldrich) with 10% fetal calf serum (FCS, Globepharm), 20 µgml
−1 
streptomycin (Sigma-Aldrich) and 20 µgml
−1 penicillin (Sigma-Aldrich) in T25 flasks (Fisher 
Scientific) kept at 37°C and 5% CO2 in an incubator. The cell population was expanded and 
brought  to  sub-confluency  nominally  three  times  per  week  using  Trypsin-EDTA  (Sigma-
Aldrich). The process of trypsinising the cell stock defines the cell passage number, which 
throughout the experiments was kept between 15 and 30. 
For the purposes of the experiment, HEK293 cells cultured in a T25 flask were suspended 
by adding 1 ml of Trypsin-EDTA and centrifuged at 0.2 g for 5 minutes in a micro-centrifuge 
tube (1.5 ml). The Trypsin was carefully removed from the medium and cells were rinsed 
twice with filtered Opti-MEM
® to remove residual Trypsin. Next, the cells were gently stirred 
in 1 ml of fresh filtered Opti-MEM
® with 1.5 µM of the injection agent PI, and passed through 
a  40 µm  filter  (BD  Falcon  Cell  Strainer,  VWR)  to  remove  any  clumps  of  adhered  cells. 
Finally, 200 µl of this cell suspension medium was aliquoted into a micro-centrifuge tube, and 
20 µl of this was loaded into the microfluidic chip for an experiment. 
The fluid medium used for filling the microfluidic chip and associated piping was also 
prepared immediately prior to the experiment. 3 ml of filtered Opti-MEM
® in a T25 flask with 
a gas permeable cap was degassed by a vacuum pump for 10 minutes, which prevented the 
formation of gas bubbles within the microfluidic chip during experiments. 3 µl of 1 mgml
−1 
water solution of PI was loaded into the flask to obtain a final PI concentration of 1.5 µM in 
degassed Opti-MEM
®. 
4. Optical setup 
The  optical  setup  is  shown  in  Fig.  3.  A  mode-locked  Titanium:Sapphire  laser  (MIRA, 
Coherent, emitting at 800 nm, repetition rate 80 MHz, 100 femtosecond (fs) pulses, 2 W 
average output power) was used for generating optical injection. A set of two half-wave plates 
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power at the  focus of the objective, and to provide an output  for a spectrum analyzer to 
monitor the mode-locked output. The beam was expanded using a x6 telescope to overfill the 
back aperture of a x60 objective lens (Nikon) of 0.8 numerical aperture, to obtain a near-
diffraction-limited sub-micron spot at the focus. The beam was directed into a microscope 
(Eclipse Ti, Nikon), with a high reflecting mirror for 800 nm as shown, to direct the beam to 
the  objective  and  split  the  laser  beam  from  the  image  for  viewing  on  the  CCD  camera 
(DFK41BU02, The Imaging Source). The transmission of the objective lens was measured 
using a ‘dual objective’ method [48], allowing the optical power at the focus to be calculated 
from the power measured at the back aperture, which was set to 90 mW at the focus for the 
data presented in the results section. This power was chosen as a physical response (bubble 
formation,  followed  by  cell  “blebbing”)  could  be  observed  at  higher  powers,  which  is 
typically associated with permanent membrane damage and subsequent cell death. 
The optical and fluid flow parameters were chosen such to mimic as closely as possible 
the situation of successful photoporation of adherent cells in a Petri dish, where typically 
between one and three laser doses of a few 10’s ms would be delivered for generating optical 
injection  [13,15,17].  A  shutter  (LST200-IR,  nmLaser  Products)  was  incorporated  into  the 
beam path to continually pulse the beam, to deliver a stream of 4 ms (125 Hz square wave 
trigger signal) laser doses to the cells as they traversed the beam. The flow rate of 1100 µms
−1 
was chosen such that a typical cell of 20 µm diameter would receive two or three 4 ms laser 
doses as it flowed through the focal spot, depending on its relative phase with the shutter. The 
laser dose duration was such to restrict each dose to within a few micrometers on the cell 
surface, whilst being within an order of magnitude of that used in photoporation of adherent 
cells. The fluence of each laser dose would therefore be sufficient to generate the required 
free-electron plasma for pore formation [26], with the physical mechanism matching that for 
photoporating adherent cells, and for similar optical powers (90 mW). Thus, it is the optical 
parameters required for successful photoporation rather than the fluid flow velocity that limits 
the throughput in this microfluidic optical injection system. 
 
Fig. 3. Schematic of the optical setup, showing the Ti: Sapphire laser, power attenuators (2x 
half-wave  plate  and  polarizing  beam-splitter),  spectrum  analyzer  (SA),  beam  expanding 
telescope, and the microscope containing: a high-NA objective lens for focusing the optical 
injection beam, and condenser lens, 800 nm high reflector (HR) and CCD camera. The PDMS 
microfluidic chip sits on the microscope stage and the fluid pumps are housed on adjacent 
raised platforms. 
5. Microfluidic optical injection 
The chip and fluidics were sterilized before each experiment, with the PDMS chip being used 
once only and autoclaved before use. The piping, syringes and connects were flushed with 
70% ethanol, rinsed with filter-sterilized deionized water and finally dried with filtered air 
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to minimize bubble formation, with filtered Opti-MEM
® solution also containing the PI to be 
injected  optically.  The  cell  injection  ports  were  sealed  during  filling  procedure  using 
Nescofilm (VWR) such that the outlet port had a higher fluid level than the inlet. This ensured 
that when inserting the cell sample, a back flow occurred to ensure the cells did not flow to 
the collection port before the system was stabilized and beam turned on. Once filled, the fluid 
switching valves were used to isolate the fluid pipes necessary for hydrodynamic focusing 
from the peristaltic pump and associated cleaning pipes, producing a closed fluid system. 
The accompanying video demonstrates the flowing of cells in the microfluidic chip for 
optical injection, and four still images from this are shown in Fig. 4. HEK293 cells were 
inserted into the chip via the micro-centrifuge tube ‘insertion port’. A 20 µl cell sample was 
pipetted into the port and allowed several minutes for it to settle onto the coverslip (base of 
the channel), as monitored on the CCD camera. Once settled, the syringe pumps were turned 
on,  generating  a  stable  hydrodynamic  focused  flow  of  cells,  close  to  the  bottom  of  the 
channel. In effect, the system is close to 2D hydrodynamic focusing, where the combination 
of gravity and 1D hydrodynamic focusing confines the cells in both vertical and horizontal 
position in the channel. The focused laser beam was positioned approximately two channel 
widths (300 µm) downstream from the focusing junction, in the centre of the cell stream and 
raised 6 µm from the base of the channel (coverslip), which was found to be most optimal for 
hitting  the  cells.  Cells  would  then  come  to  rest  under  the  ‘collection  port,’  due  to  the 
considerably larger cross section and hence slower flow channel in this region. 
 
Fig. 4. (Media 1) Frames from the accompanying video, from within the PDMS microfluidic 
chip shown schematically in Fig. 1(b). (a) Sample injection port after the insertion of cells into 
the chip. (b) Cells flowing from left to right out of the injection reservoir and towards (c) the 
hydrodynamic focusing junction, where cells (circled) can be seen flowing single file down the 
center  of  the  channel  after  the  junction.  The  focused  femtosecond  laser  beam  for  optical 
injection was situated 300 µm downstream of the junction. (d) Cell collection port after 10 
minutes showing several hundred optically injected cells that have come to rest due to the drop 
in flow velocity in this region of the chip. 
After  flowing  the cells  for typically 10  minutes, or once approximately 500 cells  had 
passed through the beam, the syringe pumps were stopped, the collection port opened, and the 
cells beneath this port removed from the chip using a pipette. We estimate that approximately 
80% of the cells could be successfully removed and collected using this method, losses mainly 
due to cells remaining in the pipette tip rather than in the chip itself. The contamination from 
un-porated cells coming from the rest of the chip is negligible during the collection process. 
Upon collection, the chip was removed, the piping rinsed and sterilized, and the system was 
ready for a new chip and cell sample. Following the removal of the optically injected cells, the 
control  samples  were  collected  from  the  injection  port.  The  contamination  from  optically 
injected cells was observed to be absolutely negligible. 
6. Efficiency of injection and cell viability 
Upon laser treatment, cells were collected from the chip collection port (for treated cells) and 
loading port (for untreated cells) into two separate micro-centrifuge tubes both containing 1 
µM of CAM in 250 µl of conditioned DMEM. Cells were incubated (37°C, 5% CO2) in two 
separated wells of 96-well Cell Culture Insert Plates (Millipore) for 15 minutes to stain cells 
with CAM, as well as allowing time for the cells to settle to the bottom of the wells. Next, 200 
µl of the surrounding solution was gently removed from both the wells. During this process, 
extra care was taken in order not to remove any of the cells deposited at the bottom of the 
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negligible levels and halt the uptake by the cells. The cells were incubated for a further 1 hour 
before examining PI (uptake due to optical injection and/or cell death) and CAM (indicating 
the  viable  cells)  fluorescence  of  both  the  treated  and  untreated  (control)  cells  under  a 
fluorescent microscope. 
Counts  of  typically  150  cells  per  experimental  run  were  conducted  for  the  two 
fluorophores. The cell samples were checked for: a) total number of cells; b) number of PI 
fluorescing cells; c) number of cells exhibiting both PI and CAM fluorescence. A typical 
image  of  the  HEK293  cells  is  shown  in  Fig.  5,  showing  the  brightfield,  PI  and  CAM 
fluorescence images. These images were obtained 24 hours post optical injection, with cells 
exhibiting healthy growth, division, continued viability and PI fluorescence. 
 
Fig. 5. Collected cells 24 hours after microfluidic photoporation, including viable optically 
injected cells (arrowed and circled). (a) Bright field microscope image showing cell attachment 
to the base of the well plate. (b) The same cells exhibiting varying levels of PI fluorescence. 
Strongly  red  fluorescing  cells  have  uptaken  large  quantities  of  PI  indicating  permanently 
compromised  dead  or  dying  cells.  Weakly  fluorescing  red  cells  are  optically  injected.  
(c) Fluorescence of CAM showing the viable cells in this field of view. The combination of PI 
fluorescence in (b) and CAM indicates a cell that has been optically injected with PI and has 
remained viable (arrowed and circled). 
Cell counts  were conducted  on the collected samples after 1.5 hours in the incubator. 
Figure 6 shows the success rate of optically injecting HEK293 cells using this microfluidic 
approach. Uptake of purely PI was found to be 42 ± 8% compared to a control of 4 ± 2%. 
Taking into account CAM, the proportion of cells that exhibited both fluorescence of PI and a 
strong CAM signal, i.e. cells that are optically injected and viable was 28 ± 4%, compared to a 
negligible control. These values are comparable to those obtained in Petri dish experiments, 
demonstrating that the technique is successful in optically injecting cells with an order of 
magnitude increase in throughput compared to a manual approach. 
 
Fig. 6. Optical injection efficiencies for HEK293 cells in a microfluidic flow. The percentage 
of cells exhibiting fluorescence of PI and those that exhibit both PI and CAM is plotted here 
against those observed in the control samples. Cells exhibiting both PI and CAM are viable 
after optical injection of PI. Data was obtained 1.5 hours after collection from the chip and 
error bars are the standard error in the mean of three experimental runs. 
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A photoporation system has been presented, where a microfluidic chip is utilized to deliver 
cells  to  a  focused  fs  laser,  producing  continuous  and  automated  optical  injection  of  a 
membrane impermeable substance to the cytoplasm of the cell. Throughputs of the order of 1 
cell per sec were obtained, enabling several thousand viable injected cells per hour and as 
such  is  the  first  demonstration  of  fs-enabled  optical  injection  on  this  scale.  The  injection 
efficiency and viability of the HEK293 mammalian cell line was confirmed using propidium 
iodide and calcein AM respectively. The injection efficiency using this technique was 42 ± 
8% compared to a control of 4 ± 2% at a laser power at the focus of 90 mW. Taking into 
account the requirement for viable cells after injection, the viable injection efficiency was 
found to be 28 ± 4%, for cells exhibited both propidium iodide and calcein AM fluorescence. 
One could expect these numbers to increase with better positioning of the height of cells 
through two dimensional hydrodynamic  focusing [49] and thus improved targeting of the 
membrane, or by means of a “diffraction-free” Bessel beam [17]. Flow velocities of 1100 ± 
100 µms
−1 were used, which in combination with a continuous stream of 4 ms femtosecond 
laser doses, potentially lead to the creation of an array of two to three “photopores” across the 
cell as it traversed the beam, thus allowing uptake of the surrounding medium. 
The work highlights the possibilities for optical injection as a realistic alternative to other 
injection techniques such as electroporation, microinjection, ballistic particle insertion (gene 
gun), or chemical or viral mediated methods. The advantages of microfluidics and fs optical 
injection are combined to provide a cell injection system with increased throughput, high 
injection efficiencies, high viability, with cheap, disposable, sterile microfluidic chips for a 
low (10’s µl) sample consumption. 
Future developments could include the combination with on-chip functionality or other 
optical  techniques,  such  as  Raman  [41]  or  fluorescence  spectroscopy  [40],  or  optical 
landscapes for active or passive sorting [43], before and/or after photoporation. Viability or 
injection efficiency measurements could be made on the chip and the sample purified, or by 
using multiple laser powers, cells could be injected or terminated in a sorting device. The 
combination of optical injection with on-chip cell culture could also be of particular interest. 
Immediate applications will be to apply the technique to the transfection of cells, including 
non adherent stem cells, through the insertion of plasmid DNA. 
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